Ribozyme mediated inactivation of the androgen receptor

Details Ribozyme mediated inactivation of the androgen receptor Ribozyme mediated inactivation of the androgen receptor

2006-06-27

2006-06-27

Schultz, J. D. (Department: 1635)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C536S024500, C514S04400A, C435S325000, C435S375000

Reexamination Certificate

active

07067256

ABSTRACT:
The present invention provides synthetic ribozyme oligonucleotides alone and within constructs. The ribozyme gene provides methods for the treatment of prostate hyperplasia and other androgen dependent pathologies. Improved therapies for such diseases are provided without significant hormonal imbalance and without surgical intervention. Also provided are techniques for selecting and synthesizing effective and specifically targeted molecular tools for use in inhibiting androgen receptor gene expression.

REFERENCES:
patent: 5556956 (1996-09-01), Roy et al.
patent: 5834440 (1998-11-01), Goldenberg et al.
patent: 6489163 (2002-12-01), Roy et al.
Albelda et al., “Gene therapy for lung disease: hype or hope,”Annals of Internal Medicine, 132(8):649-660, 2000.
Amarzguioui and Prydz, “Hammerhead ribozyme design and application,”CMLS, Cell. Mol. Life Sci., 54:1175-1202, 1998.
Asahara et al., “Stem cell therapy and gene transfer for regeneration,”Gene Therapy, 7:451-457, 2000.
Buchschacher and Wong-Staal, “Development of lentiviral vectors for gene therapy for human diseases,”Blood, 95(8):2499-2504, 2000.
Chang et al., “Molecular cloning of human and rat complementary DNA encoding androgen receptors,”Science, 240:324-6, 1988.
Chang et al., “Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors,”Proc. Nat'l. Acad. Sci. U.S.A., 85(19):7211-5, 1988.
Chatterjee et al., “Targeted overexpression of androgen receptor with a liver-specific promoter in transgenic mice,”Proc. Nat'l. Acad. Sci., 93:728-733, 1996.
Chen et al., “Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme,”Molecular Endocrinology, 12(10):1558-1566, 1998.
Eastham et al., “In vivo gene therapy with p53 or p21 adenovirus for prostate cancer,”Cancer Research, 55:5151-5155, 1995.
Esquenet et al., “Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1α, 25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cisretinoic acid, and phenylacetate,”The Prostate, 28:182-194, 1996.
Fatham et al., “Gene therapy for autoimmune disease,”Clin Immunol., 95(1):S39-S43, 2000.
Forster and Symons, “Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites.”Cell, 49:211-220, 1987.
Franklin et al., “Prostate specific gene therapy using a novel PSA promoter: in vivo studies,”Proceedings of the American Urological Association, 155:436A, 1996.
Hajjar et al., “Prospects for gene therapy for heart failure,”Circ. Res., 86:616-621, 2000.
Hanania et al., “Recent advances in the application of gene therapy to human disease,”Amer. Jrnl. Med., 99:537-552, 1995.
Haseloff and Gerlach, “Simple RNA enzymes with new and highly specific endoribonuclease activities,”Nature, 334:585-591, 1988.
Hiltunen et al., “Insights into the molecular pathogenesis of atherosclerosis and therapeutic strategie using gene transfer,”Vas. Med., 5(1):41-48, 2000.
Horoszewicz et al., “LNCaP model of human prostatic carcinoma,”Cancer Research, 43:1809-1818, 1983.
Hrouda and Dalgleish, Gene therapy for prostate cancer,Gene Therapy, 3:845-852, 1996.
Huillier et al., “Efficient and specific ribozyme-mediated reduction of bovine α-lactalbumin expression in double transgenic mice,”Proc. Natl. Acad. Sci. USA, 93:6698-6703, 1996.
Kaighn et al., “Establishment and characterization of a human prostatic carcinoma cell line (PC-3),”Investigative Urology, 17(1):16-23, 1979.
Kobayashi et al., “Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme,”Cancer Research, 54:1271-1275, 1994.
Marshall, “Gene therapy on trial,”Science, 288:951-957, 2000.
Naldini et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector,”Science, 272:263-267, 1996.
Nettlebeck et al., “Designer promoters for tumour targeting,”Trends in Genetics, 16(4):174-181, 2000.
Pyle, “Ribozymes: a distinct class of metalloenzymes,”Science, 261:709-714, 1993.
Russell and Cosset, “Modifying the host range properties of retroviral vectors,”J. Gene Med, 1(5):300-311, 1999.
Sanda et al., “Demonstration of a rational strategy for human prostate cancer gene therapy,”Jrnl. Urology, 151:622-628, 1994.
Sarver et al., “Ribozymes as potential anti HIV-1 therapeutic agents,”Science, 247:1222-1225, 1989.
Scanlon et al., “Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein,”Proc. Natl. Acad. Sci. USA, 88:10591-10595, 1991.
Sinnaeve et al., “Gene therapy in the cardiovascular system: an update,”Cardiovascular Research, 44:498-506, 1999.
Snyder, “Adeno-associated virus-mediated gene delivery,”J. Gene Med., 1(3):166-175, 1999.
Steiner et al., “Gene therapy for the treatment of advanced prostate cancer by in vivo transduction with prostate-targeted retroviral vectors expressing antisense C-mycRNA,”Proceedings of the American Urological Association, 155:340A, 1996.
Suzuki et al., “Adenovirus-mediated ribozyme targeting of HER-2
euinhibits in vivo growth of breast cancer cells,”Gene Therapy, 7:241-248, 2000.
Uhlenbeck, “A small catalytic oligoribonucleotide,”Nature, 328:596-600, 1987.
Umekita et al., “Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride,”Proc. Nal'l Acad. USA, 93(21):11802-11807, 1996.
Urtizberea, “Therapies in muscualr dystrophy: current concepts and future prospects,”Eur. Neurol., 43:127-132, 2000.
Zabner et al., “Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis,”Cell, 75:207-216, 1993.
Chen, Molecular strategies for selective inhibition of androgen receiptor gene expression,A Dissertation presented to the Faculty of the University of Texas Graduate School of Biomedical sciences at San Antonio in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Cellular and Structural Biology, Mar., 1997; Also, vol. 58/03 B of Dissertation Abstracts International , p. 1103, 1997, Abstract only.
Chen and Roy, “Specific inactivation of the androgen receptor messenger RNA by a hammerhead ribozyme,”Premier Event in 10thInternational Congress of Endocrinol, 10:87, 1996.
Wu and Ataai, “Production of viral vectors for gene therapy application,”Biochemical Engineering, 11:205-208, 2000.

Affiliated with

Also associated with

Rating

Ribozyme mediated inactivation of the androgen receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ribozyme mediated inactivation of the androgen receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ribozyme mediated inactivation of the androgen receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3666838